Bayer stock edges higher as FDA approves Kerendia for new kidney disease use

Bayer stock (ISIN DE000BAY0017) is trading just below the 49-euro mark on Xetra on September 17, 2026 as investors react to a fresh U.S. FDA approval for the company’s kidney drug Kerendia.

FDA expands Kerendia label in the U.S.

According to RTTNews on September 17, 2026, the U.S. Food and Drug Administration has approved Bayer’s non-steroidal mineralocorticoid receptor antagonist Kerendia (finerenone) for adult patients with chronic kidney disease associated with type 1 diabetes.

The new indication is Kerendia’s third in the U.S. market and specifically covers reducing urinary albumin-to-creatinine ratio in adults with chronic kidney disease linked to type 1 diabetes, which is expected to lower the risk of sustained decline in kidney function and progression to end-stage kidney disease, as outlined by Business Wire.

As Business Wire reports, Kerendia is described as the first new FDA-approved treatment option in more than 30 years for adult patients in this chronic kidney disease and type 1 diabetes population, underlining the strategic importance of the drug for Bayer’s cardiorenal franchise.

In the broader German equity market context, pharma major Bayer was cited as edging modestly higher after the Kerendia approval, according to a German market wrap from finanzen.ch on September 17, 2026.

Stock trades around 49 euros amid intraday swings

During Xetra trading on September 17, 2026, Bayer shares showed mixed intraday moves around the 49-euro level. In late morning trading, the stock gained about 0.8 percent to 49.38 euros, with an intraday high at 49.65 euros, as reported by finanzen.ch.

By around 12:28 local time on September 17, 2026, the tone had turned slightly negative, with Bayer shares easing by about 0.1 percent to 48.93 euros on Xetra, having opened the session at 49.27 euros and briefly dipping to 48.90 euros, according to a mid-day update from finanzen.ch.

The trading activity reflects active investor interest: by mid-day on September 17, 2026, about 323,344 Bayer shares had changed hands on Xetra, based on data cited by finanzen.ch.

Separate trading data from the Tradegate Exchange show recent transactions in Bayer shares around the high 48-euro range, including prints at 48.80 euros and 48.79 euros shortly after 13:06 on September 17, 2026, as per the order book overview on Tradegate. These secondary-market levels are slightly below the morning Xetra peak but broadly in line with the mid-day Xetra quotations.

For U.S. investors, the Bayer American depositary receipt BAYRY showed a modest gain, quoted at 14.05 dollars and up 0.11 percent on September 17, 2026, while another Bayer-related listing BAYZF was indicated at 56.38 dollars and down about 1.83 percent, according to a Business Wire releases overview on Barchart.

Fundamental backdrop and earnings context

The latest FDA decision adds to Bayer’s pharmaceuticals portfolio at a time when the company is working to strengthen its balance sheet and investment capacity. As Alternatives Watch reported on September 16, 2026, Apollo-managed funds recently closed a 3 billion euro high-grade capital solution for Bayer within the manager’s roughly 130 billion dollar High Grade Capital Solutions strategy, reinforcing Bayer’s financial flexibility.

While the most recent detailed quarterly or half-year figures are not explicitly broken out in the week’s search results, investors are aware that guidance and profitability metrics from Bayer’s latest reporting period underpin expectations for how much incremental revenue and earnings Kerendia’s expanded use can deliver over time. Historical reporting indicates that pharmaceuticals have been a central earnings driver alongside crop science, and the addition of a new cardiorenal indication helps diversify future cash flows compared with legacy businesses that have faced legal and competitive pressures.

For a sense of how structural products reference Bayer as an underlying, a recent data set for a Bayer-linked equity-linked note shows a base price of 42.69 euros and a current underlying price of 49.11 euros in Xetra trading, implying the stock is trading about 6.42 euros, or 13.07 percent, above that base level as of the morning of September 17, 2026, according to an instruments overview on onvista. This quantified comparison underscores how the recent share price is positioned relative to structured-product strike levels.

Against this backdrop, the FDA approval for Kerendia’s new use case is seen as a potential medium-term support for revenue growth in Bayer’s pharmaceuticals segment. The fact that the drug now covers chronic kidney disease associated with both type 2 and type 1 diabetes broadens its addressable patient base, which could help offset headwinds in other areas of the group’s portfolio.

Analyst and market reaction

Sector commentary from finanzen.ch indicates that German equities were boosted by falling oil prices and lower bond yields on September 17, 2026, and that Bayer participated modestly in that positive sentiment following the Kerendia announcement.

At the same time, intraday reports from finanzen.ch and finanzen.ch show that Bayer’s share price fluctuated between modest gains and slight losses during the day, suggesting that while the FDA news is positive, it is being weighed against other factors such as overall sector positioning, valuation, and existing legal and restructuring risks.

Investors also factor in capital-structure moves like the 3 billion euro Apollo transaction highlighted by Alternatives Watch, which can influence views on Bayer’s credit metrics, funding costs and capacity to invest in growth areas such as innovative pharmaceuticals.

Stock level and investor takeaway

As of the latest Xetra indications available for September 17, 2026, Bayer stock is changing hands around the high 48-euro to low 49-euro range, with morning highs reported at 49.65 euros and mid-day levels closer to 48.93 euros. This places the shares comfortably above referenced base prices from structured notes around 42.69 euros, yet still below previously seen higher peaks, leaving room for investors to reassess upside potential as the fundamental impact of the Kerendia approval and capital solution transaction becomes clearer over coming quarters.

More news and analyses on Bayer stock